Tobramycin in bronchial secretions

Area of Science:

• Pharmacology
• Respiratory Medicine
• Infectious Diseases

Background:

• Lower respiratory tract infections often involve Pseudomonas.
• Effective antibiotic penetration into bronchial secretions is crucial for treatment.
• Tobramycin sulfate is an aminoglycoside antibiotic used for serious infections.

Purpose of the Study:

• To investigate the penetration of tobramycin sulfate into canine lower respiratory tract secretions.
• To determine the concentration and time course of tobramycin in bronchial secretions after intravenous administration.

Main Methods:

• A dog model was used to study tobramycin sulfate penetration.
• An intravenous dose of 1.7 mg/kg tobramycin was administered.
• Bronchial secretions were collected and analyzed for tobramycin concentration over time.

Main Results:

• Tobramycin sulfate was detected promptly in bronchial secretions after intravenous injection.
• Peak concentrations in bronchial secretions were typically reached 2 hours post-injection (mean 1.15 mug/ml).
• Maximum tobramycin concentrations achieved were comparable to mean inhibitory concentrations for approximately 80% of Pseudomonas isolates.

Conclusions:

• Intravenous tobramycin sulfate demonstrates good penetration into canine respiratory tract secretions.
• Achieved concentrations suggest potential efficacy against Pseudomonas in lower respiratory tract infections.
• Further studies may support tobramycin's role in managing specific respiratory infections.